Impact: Proximal complement inhibition is cost-saving for patients with suboptimal response on C5 inhibitor therapy in the United States and can be cost-saving in international jurisdictions (Penn-Yale collaboration).

Impact: Decreasing the need for hospital, emergency, and procedural care with the use of bevacizumab (vs no bevacizumab) improves quality-adjusted life expectancy and saves costs in the care of people living with HHT (MGH-Yale collaboration). ASH Abstract Achievement Award, Best of ASH (HTRS) (D. Wang)

Impact: Faster adjudication of iTTP diagnosis with rapid ADAMTS13 is cost-saving for patients suspected to have iTTP, regardless of treatment regimen (Hopkins-Penn-Yale collaboration). ASH Abstract Achievement Award, Best of ASH for North America, Best of ASH (HTRS), UK TTP Registry/US TMA Selection (C. Allen)

Impact: Supporting the mission of the 501(c)(3) Alloantibody Exchange www.alloantibody.org. 2022 ASH Press Program Selection.

Impact: For treatment funding decisions, even if gene therapy is cost-ineffective by conventional CEA standards, it is an equitable therapy per DCEA standards in the United States for patients with sickle cell disease. 2022 ASH Press Program Selection.